news > tag > isosolutions

Society of Nuclear Medicine and Molecular Imaging Annual Meeting 2019

David T. Drummond ⎜Jun 8, 2019 ⎜ Calendar

SNMMI 2019 Annual Meeting, June 22-25, 2019 in Anaheim, California.
isoSolutions is pleased to inform you that we will attend the Annual Meeting of the Society of Nuclear Medicine and Molecular Imaging (SNMMI). (more…)

Tags:

Bone marrow cell homing to sites of acute tibial fracture: 89Zr-oxine cell labeling with positron emission tomographic imaging in a mouse model

Kevin Yang ⎜Feb 13, 2019 ⎜ Industry

Bone fracture healing is dependent upon the rapid migration and engraftment of bone marrow (BM) progenitor and stem cells to the site of injury. Stromal cell-derived factor-1 plays a crucial role in recruiting BM cells expressing its receptor CXCR4. Recently, a CXCR4 antagonist, plerixafor, has been used to mobilize BM cells into the blood in efforts to enhance cell migration to sites of injury presumably improving healing. (more…)

Tags:

Chinese Lunar New Year, Year of the Pig!

David T. Drummond ⎜Feb 5, 2019 ⎜ Company

Chinese Lunar New Year

isoSolutions wishes everyone health and prosperity in the Year of the Pig!

Tags:

isoSolutions Offers GMP Grade Non-carrier Added Lutetium-177

David T. Drummond ⎜Nov 19, 2018 ⎜ Industry

An agreement signed with SpectronRx, an Indiana, USA radiopharmaceutical manufacturer, designates isoSolutions as the exclusive distributor in Latin America and Canada of Spectron’s GMP grade non-carrier added (nca) Lutetium-177 radiochemical.

Non-carrier added (nca) Lutetium-177 (Lu-177) is a radioisotope used for therapeutic purposes. (more…)

Tags:

Safety, Pharmacokinetics, and Dosimetry of a Long-Acting Radiolabeled Somatostatin Analog 177Lu-DOTA-EB-TATE in Patients with Advanced Metastatic Neuroendocrine Tumors

Kevin Yang ⎜Nov 5, 2018 ⎜ Industry

Radiolabeled somatostatin analog therapy has become an established treatment method for patients with well to moderately differentiated unresectable or metastatic neuroendocrine tumors (NETs). The most frequently used somatostatin analogs in clinical practice are octreotide and octreotate. (more…)

Tags:

First-in-human study of 177Lu-EB-PSMA-617 in patients with metastatic castration-resistant prostate cancer

Kevin Yang ⎜Sep 12, 2018 ⎜ Industry

This first-in-human study demonstrated that 177Lu-EB-PSMA-617 had higher accumulation in mCRPC and that low imaging dose appears to be effective in treating tumors with high 68Ga-PSMA-617 uptakes. Elevated uptakes of 177Lu-EBPSMA-617 in kidneys and red bone marrow were well tolerated at the administered low dose. Further investigations with increased dose and frequency of administration are warranted. (more…)

Tags:

Single Low-Dose Injection of Evans Blue Modified PSMA-617 Radioligand Therapy Eliminates Prostate-Specific Membrane Antigen Positive Tumors

Kevin Yang ⎜Sep 6, 2018 ⎜ Industry

Prostate cancer is the most frequently diagnosed malignant tumor in men worldwide. Prostate-specific membrane antigen (PSMA) is a surface molecule specifically expressed by prostate tumors and has been shown to be a valid target for internal radionuclide therapy in both preclinical and clinical settings. The most common radiotherapeutic agent is the small molecule 177Lu-PSMA-617, (more…)

Tags:

United Pharmacy Partners (UPPI, LLC) 2018 Annual Meeting

Patricia Acton ⎜Sep 5, 2018 ⎜ Calendar

isoSolutions will be attending the United Pharmacy Partners (UPPI, LLC) 2018 Annual Meeting to be held in San Antonio, TX September 12 to 15, 2018. (more…)

Tags:

Y-90 Radioembolization Long-Term Outcomes in a 185-Patient Cohort

Kevin Yang ⎜Jul 26, 2018 ⎜ Industry

Y-90 radioembolization for HCC patients with PVT appears to have an acceptable safety profile, with better survival in CP-A patients than in CP-B patients. This study confirms prior reports of survival in PVT patients treated with Y-90 radioembolization, and survival after Y-90 radioembolization appears to exceed that in
similar patients treated with systemic therapies. Despite the negative studies recently reported, Y-90 radioembolization is a reasonable treatment option in properly selected PVT patients. Further controlled studies are needed to compare it with systemic therapies or other locoregional treatments for advanced-stage HCC.

Nadine Abouchaleh1, Ahmed Gabr1, Rehan Ali1, Ali Al Asadi1, Ronald A. Mora1, Joseph Ralph Kallini1, Samdeep Mouli1, Ahsun Riaz1, Robert J Lewandowski1, and Riad Salem1–3

Info on purchasing Y-90, please contact sales@isosolutions.com

Read the full article PDF

Tags:

19th China Cardiovascular and Nuclear Medicine Annual meeting

Hans Peng ⎜Jul 11, 2018 ⎜ Industry

isoSolutions Marketing and Management will send its representative in China, Eric Huang to the 19th China Cardiovascular and Nuclear Medicine Annual meeting organized by Chinese Society of Nuclear Medicine (http://www.csnm.com.cn/) in Sichuan, China.

The 19th China Cardiovascular and Nuclear Medicine Annual Meeting will be held in Chengdu, Sichuan from July 12 to July 15, 2018. (more…)

Tags:

SNMMI Image of the Year: PSMA PET Imaging of Theranostic for Advanced Prostate Cancer

David T. Drummond ⎜Jun 29, 2018 ⎜ Industry

PHILADELPHIA (Embargoed until 6:30 p.m. EDT, Tuesday, June 26, 2018) – In the battle against metastatic castrate-resistant prostate cancer, studies have demonstrated a high response rate to radionuclide therapy targeting prostate specific membrane antigen (PSMA) with the radionuclide lutetium-177 (177Lu). (more…)

Tags:

Targeted a-Therapy of Metastatic Castration-Resistant Prostate Cancer Analysis Suggests Efficacy Regarding Duration of Tumor Control

Kevin Yang ⎜Jun 6, 2018 ⎜ Industry

A positive response for surrogate parameters demonstrates remarkable antitumor activity for 225Ac-PSMA-617. Swimmer-plot analysis indicates a promising duration of tumor control, especially considering the unfavorable prognostic profile of the selected advanced-stage patients. Xerostomia was the main reason patients discontinued therapy or refused additional administrations and was in the same dimension as nonresponse; this finding indicates that further modifications of the treatment regimen with regard to side effects might be necessary to further enhance the therapeutic range.

Clemens Kratochwil1, Frank Bruchertseifer2, Hendrik Rathke1, Markus Hohenfellner3, Frederik L. Giesel1, Uwe Haberkorn*1,4, and Alfred Morgenstern*2

Info on purchasing Ac-225, please contact sales@isosolutions.com .

Read the full article PDF

Tags:

Scholarship Awarded 2018

David T. Drummond ⎜May 7, 2018 ⎜ Industry

The Armstrong-Lepeska Science Marketing Scholarship, sponsored by isoSolutions, has been awarded to two more students. This scholarship is granted to a student at Langara College in Vancouver.  To highlight the importance of marketing and sales of high-technology, scientifically-intensive products, the scholarship awards a student in a scientific discipline who completes a course in Marketing.

(more…)

Tags:

Society of Nuclear Medicine and Molecular Imaging Annual Meeting 2018

David T. Drummond ⎜Jan 19, 2018 ⎜ Calendar

2018 June 23 to 26 @ Pennsylvania Convention Center, Headquarter Hotel: Philadelphia Marriott

isoSolutions is pleased to inform you that we will attend the Annual Meeting of the Society of Nuclear Medicine and Molecular Imaging (SNMMI). You can find us at Booth 1001 in the Pennsylvania Convention Center. We hope to see you there and we can arrange a time and place to meet if you wish.

We look forward to seeing you in Philadelphia, Pennsylvania.

Tags:

Canadian Nuclear Medicine Scientific Meeting 2018

David T. Drummond ⎜Jan 19, 2018 ⎜ Calendar

isoSolutions will be present at the Canadian Nuclear Medicine Annual Scientific Meeting in Vancouver, BC from 2018–03–23 to 2018–03–24.

 

More info about the event on canm-acmn.ca

Tags:

Customer Service Manager Appointed

David T. Drummond ⎜Nov 3, 2017 ⎜ Company

Mr. Gabriel Freitas has been appointed as the Customer Service Manager for isoSolutions.  This new position provides general administrative support to the team, with primary responsibility for customer and supplier support. The main responsibilities of this position are to maintain the order desk and customer support.The Customer Service Manager will prepare quotations; receive, enter, acknowledge and distribute purchase orders and invoices; check and distribute shipping documents; process order changes; and correspond with suppliers, customers and sales managers regarding orders and new product requests. Other duties will include organizing tradeshows and logistics for tradeshows; coordinating website maintenance; preparing and distributing newsletters; managing promotional brochures; and assisting with staff training programs. (more…)

Tags:

Scholarship Awarded

David T. Drummond ⎜Mar 29, 2017 ⎜ Industry

The Armstrong-Lepeska Science Marketing Scholarship, sponsored by isoSolutions, has been awarded to two more students.

This scholarship is granted to a student at Langara College in Vancouver.  To highlight the importance of marketing and sales of high-technology, scientifically-intensive products, the scholarship awards a student in a scientific discipline who completes a course in marketing.  This year, two students were funded:  Mr. Hazhir Goodarznia and Mr. Adrian Wong (more…)

Tags:

isoSolutions Plans New Website

David T. Drummond ⎜Dec 27, 2016 ⎜ Company

To reflect additions to our product line and expansion of our business, isoSolutions will install a new, updated web site early in 2017. The new web site will incorporate new features that will be of interest to our visitors and will help our clients and partners to find the information they are seeking.

The new web site will be designed and installed by Mr. Bruno Tomazelli, who has joined our team. Bruno is a graphic designer with over five years of experience in advertising. (more…)

Tags:

XXX Brazilian Nuclear Medicine Congress 2016

David T. Drummond ⎜Nov 1, 2016 ⎜ Calendar

isoSolutions will be present at the Brazilian Nuclear Medicine Congress from 2016–11–12 to 2016–11–14.

Tags:

Canadian Nuclear Medicine Congress

David T. Drummond ⎜Oct 25, 2016 ⎜ Calendar

isoSolutions will be present at the Canadian Nuclear Medicine Annual Scientific Meeting in Halifax, Nova Scotia from 2016–04–21 to 2016–04–24.

Tags:

XXV ALASBIMN Congress

David T. Drummond ⎜Sep 1, 2016 ⎜ Calendar

isoSolutions will be present at the XXV ALASBIMN Congress in Punta del Este, Uruguay from 2015–11–18 to 2015–11–21.

Tags:

isoSolutions Presents Wide Range of Products at Annual Meeting of Society of Nuclear Medicine and Medical Imaging

David T. Drummond ⎜Jun 1, 2016 ⎜ Calendar

The annual meeting of the Society of Nuclear Medicine and Medical Imaging (SNNMI) will be held in Vancouver, Canada from 08 June to 12 June 2013. isoSolutions Marketing & Management Inc. will be exhibiting a wide range of nuclear medicine products.

isoSolutions is presenting a package of products and services for diagnostic and therapeutic radiolabeling applications — a complete labeling solution. isoSolutions can provide a complete range of radioisotopes, including a Ga-68 Generator (iThemba), Lu-177, Y-90, Re-188 and I-131. These products are complemented by a state-of-the-art automated labeling module (Trasis All-in-One) and a complete range of labeling peptides. Finally, expert, experienced consulting services are offered for radiochemistry, licensing (preparation of CMC sections, INDs, DMFs) and grant applications.

isoSolutions also offers an extensive catalog of radiochemicals, radiopharmaceuticals, in-vivo cold kits, stable isotopes, labeled compounds, reagents, shipping containers, laboratory equipment and calibration sources from high quality, reliable suppliers. With isoSolutions, customers can obtain a one-stop shopping service as well as technical support.

David T. Drummond, Managing Director of isoSolutions, states, “We are looking forward to welcoming our customers from North America, South America, China and elsewhere to our booth #1336 at the SNNMI exhibition. We are especially proud that this international congress is being held in our hometown of Vancouver.”

Tags: